Literature DB >> 28081635

Highly sensitive faecal DNA testing of TWIST1 methylation in combination with faecal immunochemical test for haemoglobin is a promising marker for detection of colorectal neoplasia.

Yutaka Suehiro1, Yibo Zhang1, Shinichi Hashimoto2, Taro Takami2, Shingo Higaki3, Yoshitaro Shindo4, Nobuaki Suzuki4, Shoichi Hazama5, Masaaki Oka4, Hiroaki Nagano4, Isao Sakaida2, Takahiro Yamasaki1.   

Abstract

Background As TWIST1 methylation is specific to colorectal neoplasia, detection of TWIST1 methylation from faeces samples might be useful for colorectal neoplasia screening. However, because the content of human DNA in faeces is very small, it is very difficult to detect TWIST1 methylation by conventional bisulphite-based methylation assays. Therefore, we developed a new methylation assay without bisulphite treatment, the combined restriction digital PCR assay, and evaluated its sensitivity and specificity in combination with and without the faecal immunochemical test for haemoglobin for colorectal neoplasia detection from faeces samples. Methods For the combined restriction digital PCR assay, DNA was treated with three methylation-sensitive restriction enzymes and an exonuclease, followed by measurement of TWIST1 methylation level by droplet digital PCR. Faecal DNA testing and faecal immunochemical test for haemoglobin were performed on 109 patients with colorectal neoplasia and 10 control individuals. Results Basic performance testing showed that the combined restriction digital PCR assay enabled detection of 0.14% of the TWIST1 methylation level for the lymphocyte DNA. The combined restriction digital PCR assay from faeces samples had a sensitivity of 22.2% (95% confidence interval, 2.8-60.0%) for non-advanced adenoma, 47.1% (95% confidence interval, 23.0-72.2%) for advanced adenoma, and 33.7% (95% confidence interval, 23.7-45.0%) for colorectal cancer, and a specificity of 100.0%. Combination of faecal immunochemical test for haemoglobin and faecal combined restriction digital PCR assay increased sensitivity to 82.4% (95% confidence interval, 56.6-96.2%) for the detection of advanced adenoma. Conclusions We developed the combined restriction digital PCR assay, a possible highly sensitive methylation assay. Combination of faecal combined restriction digital PCR assay with faecal immunochemical test for haemoglobin may provide an alternative screening strategy for colorectal neoplasia, especially for potentially precancerous lesions.

Entities:  

Keywords:  Advanced adenoma; TWIST1; colorectal cancer; digital PCR; faecal DNA test; faecal immunochemical test; methylation

Mesh:

Substances:

Year:  2017        PMID: 28081635     DOI: 10.1177/0004563217691064

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  8 in total

Review 1.  Effect of gut microbiota in the colorectal cancer and potential target therapy.

Authors:  Junchuan Li; Yuzhou Zhu; Lie Yang; Ziqiang Wang
Journal:  Discov Oncol       Date:  2022-06-24

2.  Blood free-circulating DNA testing by highly sensitive methylation assay to diagnose colorectal neoplasias.

Authors:  Yutaka Suehiro; Shinichi Hashimoto; Shingo Higaki; Ikuei Fujii; Chieko Suzuki; Tomomi Hoshida; Toshihiko Matsumoto; Yuko Yamaoka; Taro Takami; Isao Sakaida; Takahiro Yamasaki
Journal:  Oncotarget       Date:  2018-03-30

3.  Highly sensitive detection of sentinel lymph node metastasis of breast cancer by digital PCR for RASSF1A methylation.

Authors:  Mizuho Abe; Naofumi Kagara; Tomohiro Miyake; Tomonori Tanei; Yasuto Naoi; Masafumi Shimoda; Kenzo Shimazu; Seung Jin Kim; Shinzaburo Noguchi
Journal:  Oncol Rep       Date:  2019-10-10       Impact factor: 3.906

Review 4.  The Intestinal Microbiota and Colorectal Cancer.

Authors:  Yiwen Cheng; Zongxin Ling; Lanjuan Li
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

5.  Blood Free-Circulating DNA Testing of Methylated RUNX3 Is Useful for Diagnosing Early Gastric Cancer.

Authors:  Eizaburou Hideura; Yutaka Suehiro; Jun Nishikawa; Takuya Shuto; Hiroyuki Fujimura; Shunsuke Ito; Atsushi Goto; Kouichi Hamabe; Issei Saeki; Takeshi Okamoto; Shingo Higaki; Ikuei Fujii; Chieko Suzuki; Tomomi Hoshida; Toshihiko Matsumoto; Taro Takami; Isao Sakaida; Takahiro Yamasaki
Journal:  Cancers (Basel)       Date:  2020-03-26       Impact factor: 6.639

6.  Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing Hepatocellular Carcinoma.

Authors:  Yurika Kotoh; Yutaka Suehiro; Issei Saeki; Tomomi Hoshida; Masaki Maeda; Takuya Iwamoto; Toshihiko Matsumoto; Isao Hidaka; Tsuyoshi Ishikawa; Taro Takami; Shingo Higaki; Ikuei Fujii; Chieko Suzuki; Yoshitaro Shindo; Yukio Tokumitsu; Hiroaki Nagano; Isao Sakaida; Takahiro Yamasaki
Journal:  Hepatol Commun       Date:  2020-01-02

7.  Fecal Enterotoxigenic Bacteroides fragilis-Peptostreptococcus stomatis-Parvimonas micra Biomarker for Noninvasive Diagnosis and Prognosis of Colorectal Laterally Spreading Tumor.

Authors:  Xiaonan Shen; Jialu Li; Jiaqi Li; Yao Zhang; Xiaobo Li; Yun Cui; Qinyan Gao; Xiaoyu Chen; Yingxuan Chen; Jing-Yuan Fang
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244

8.  Fecal DNA Testing of TWIST1 Methylation Identifies Patients With Advanced Colorectal Adenoma Missed by Fecal Immunochemical Test for Hemoglobin.

Authors:  Yutaka Suehiro; Shinichi Hashimoto; Atsushi Goto; Yuko Yamaoka; Naoki Yamamoto; Nobuaki Suzuki; Shingo Higaki; Ikuei Fujii; Chieko Suzuki; Toshihiko Matsumoto; Tomomi Hoshida; Michiko Koga; Takeya Tsutsumi; Lay Ahyoung Lim; Yasuo Matsubara; Taro Takami; Shin Yoshida; Shoichi Hazama; Hiroshi Yotsuyanagi; Hiroaki Nagano; Isao Sakaida; Takahiro Yamasaki
Journal:  Clin Transl Gastroenterol       Date:  2020-06       Impact factor: 4.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.